Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

February 2025

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 FEBRUARY 2025

- Amoxicillin with clavulanic acid (Synermox) inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial – new listing and addition of PSS
- Amoxicillin with clavulanic acid (Amoxiclav Multichem) inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial – to be delisted 1 September 2025
- Atorvastatin (Lorstat) tab 10 mg and 80 mg, 30 tab pack – new listing
- Baricitinib (Olumiant) tab 2 mg and 4 mg – delisted 1 February 2025
- Bedaquiline (Sirturo) tab 100 mg – delisted 1 February 2025
- Bee venom (VENOX) initiation kit – 1 vial freeze dried venom with diluent – new listing
- Bee venom (VENOX) initiation kit – 5 vials freeze dried venom with diluent – to be delisted 1 May 2025
- Carboplatin (DBL Carboplatin) inj 10 mg per ml, 45 ml vial – new listing
- Clomipramine hydrochloride (APO Clomipramine) tab 25 mg – new listing and addition of PSS
- Clomipramine hydrochloride (Clomipramine Teva) tab 10 mg and 25 mg and cap 10 mg and 25 mg – to be delisted 1 July 2025
- Cyproterone acetate (Siterone) tab 50 mg and 100 mg – price increase and addition of PSS
- Denosumab (Xgeva) inj 120 mg per 1.7 ml vial – new listing
- Denosumab inj 60 mg prefilled syringe (Prolia) and inj 120 mg per 1.7 ml vial (Xgeva) – note added and amended restriction criteria
- Diclofenac sodium (Diclofenac Devatis) eye drops 0.1%, single dose, 10 dose and 30 dose – new listing and addition of PSS
- Efavirenz with emtricitabine and tenofovir disoproxil (Triovir) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) – new listing
- Entacapone (Entapone) tab 200 mg – new listing and addition of PSS
- Entacapone (Comtan) tab 200 mg – to be delisted 1 July 2025
- Enteral feed 1.5 kcal/ml (Fresubin HP Energy) liquid 7.5 g protein, 17 g carbohydrate and 5.8 g fat per 100 ml, bag, 1,000 ml – delisted 1 February 2025
- Enteral feed 1 kcal/ml (Fresubin Original) liquid 3.8 g protein, 13.8 g carbohydrate and 3.4 g fat per 100 ml, bag, 1,000 ml – delisted 1 February 2025
- Enteral feed with fibre 1 kcal/ml (Fresubin Original Fibre) liquid 3.8 g protein, 13.0 g carbohydrate, 3.4 g fat and 1.5 g fibre per 100 ml, bag, 1,000 ml – delisted 1 February 2025

Summary of decisions – effective 1 February 2025 (continued)

- Enteral feed with fibre 1.5 kcal/ml (Fresubin HP Energy Fibre) liquid 7.5 g protein, 16.2 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bag, 1,000 ml – delisted 1 February 2025
- Enteral feed 2 kcal/ml (Fresubin 2kcal HP) liquid 10 g protein, 17.5 g carbohydrate and 10 g fat per 100 ml, bag – delisted 1 February 2025
- Fexofenadine hydrochloride (Fexaclear) tab 120 mg and 180 mg – new listing and addition of PSS
- High protein enteral feed 1.2 kcal/ml (Fresubin Intensive) liquid 10 g protein, 12.9 g carbohydrate and 3.2 g fat and 0.64 g fibre per 100 ml, bag, 500 ml – delisted 1 February 2025
- Hydroxocobalamin (Hydroxocobalamin Panpharma) inj 1 mg per ml, 1 ml ampoule – price increase and addition of PSS
- Itraconazole (Itracap) cap 100 mg – new listing
- Levodopa with carbidopa and entacapone (Stalevo) tab 50 mg with carbidopa 12.5 mg and entacapone 200 mg, tab 100 mg with carbidopa 25 mg and entacapone 200 mg, tab 150 mg with carbidopa 37.5 mg and entacapone 200 mg and tab 200 mg with carbidopa 50 mg and entacapone 200 mg – new listing and addition of PSS
- Nepafenac eye drops 0.3% – to be delisted 1 July 2025
- Pazopanib (Pazopanib Teva and Votrient) tab 200 mg and 400 mg – amended restriction criteria
- Paediatric enteral feed 1 kcal/ml (Frebini Original) liquid 2.5 g protein, 12.5 g carbohydrate and 4.4 g fat per 100 ml, 500 ml – delisted 1 February 2025
- Paediatric enteral feed 1.5 kcal/ml (Frebini Energy) liquid 3.8 g protein, 18.7 g carbohydrate and 6.7 g fat per 100 ml, 500 ml – delisted 1 February 2025
- Paediatric enteral feed with fibre 1 kcal/ml (Frebini Original Fibre) liquid 2.5 g protein, 12.1 g carbohydrate, 4.5g fat and 0.8 g fibre per 100 ml, 500 ml – delisted 1 February 2025
- Paediatric enteral feed with fibre 1.5 kcal/ml (Frebini Energy Fibre) liquid 3.8 g protein, 18.1 g carbohydrate, 6.7 g fat and 1.1 g fibre per 100 ml, 500 ml – delisted 1 February 2025
- Peptide-based enteral feed 1kcal/ml (Survimed OPD) liquid 4.5 g protein, 14.3 g carbohydrate and 2.8 g fat per 100 ml, bag, 500 ml – delisted 1 February 2025
- Salbutamol (SalAir) aerosol inhaler, 100 mcg per dose, 200 dose – price increase
- Sunitinib (Sunitinib Pfizer) cap 12.5 mg, 25 mg and 50 mg – amended restriction criteria

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 February 2025

ALIMENTARY TRACT AND METABOLISM

26 HYDROXOCOBALAMIN (↑ price and addition of PSS)
Inj 1 mg per ml, 1 ml ampoule – **5% DV Jul-25 to 2027** ..... 3.95 3 **Hydroxocobalamin Panpharma**

CARDIOVASCULAR SYSTEM

50 ATORVASTATIN (new listing)
Tab 10 mg ..... 0.31 30 Lorstat
Tab 80 mg ..... 1.52 30 Lorstat

HORMONE PREPARATIONS

77 CYPROTERONE ACETATE (↑ price and addition of PSS)
Tab 50 mg – **5% DV Jul-25 to 2027** ..... 17.05 50 **Siterone**
Tab 100 mg – **5% DV Jul-25 to 2027** ..... 31.00 50 **Siterone**

INFECTIONS

91 AMOXICILLIN WITH CLAVULANIC ACID (new listing and addition of PSS)
Inj 500 mg with clavulanic acid 100 mg vial
– **5% DV Sep-25 to 2027** ..... 22.48 10 **Synermox**
Inj 1,000 mg with clavulanic acid 200 mg vial
– **5% DV Sep-25 to 2027** ..... 29.61 10 **Synermox**
Note – Amoxiclav Multichem inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial to be delisted from 1 September 2025.

95 ITRACONAZOLE (new listing)
➔ Cap 100 mg ..... 27.32 60 Itracap

98 BEDAQUILINE (delisted)
➔ Tab 100 mg ..... 24,162.00 188 Sirturo
Note – Sirturo tab 100 mg delisted 1 February 2025.

102 EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing)
➔ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) ..... 106.88 30 Triovir

MUSCULOSKELETAL SYSTEM

112 DENOSUMAB (new listing)
Note: Denosumab inj 60 mg per 1 ml pre-filled syringe is Medsafe approved for use in osteoporosis. Denosumab inj 120 mg per 1.7 ml vial is Medsafe approved for use in hypercalcaemia of malignancy
➔ Inj 120 mg per 1.7 ml vial ..... 500.00 1 Xgeva

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 February 2025 (continued)

112 DENOSUMAB (note added and amended restriction criteria)

Note: Denosumab inj 60 mg per 1 ml pre-filled syringe is Medsafe approved for use in osteoporosis. Denosumab inj 120 mg per 1.7 ml vial is Medsafe approved for use in hypercalcaemia of malignancy

➔ Inj 60 mg prefilled syringe	326.00	1	Prolia
➔ Inj 120 mg per 1.7 ml vial	500.00	1	Xgeva

Initiation – **Osteoporosis**

All of the following:

1 The patient has severe, established osteoporosis; and
2 Either:
  2.1 The patients is female and postmenopausal; or
  2.2 The patient is male or non-binary; and
3 Any of the following:
  3.1 History of one significant osteoporotic fracture, demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to -2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
  3.2 History of one significant osteoporotic fracture, demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
  3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
  3.4 Documented T-Score less than or equal to -3.0 (see Note); or
  3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent; at adequate doses (see Notes); and
6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Initiation – Hypercalcaemia

Both:

1 Patient has hypercalcaemia of malignancy; and
2 Patient has severe renal impairment.

Note:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

Changes to Section H Part II – effective 1 February 2025 (continued)

NERVOUS SYSTEM

118 ENTACAPONE (new listing and addition of PSS)

Tab 200 mg – **5% DV Jul-25 to 2027**	13.73	100	**Entapone**

Note – Comtan tab 200 mg to be delisted 1 July 2025.

119 LEVODOPA WITH CARBIDOPA AND ENTACAPONE (new listing and addition of PSS)

Tab 50 mg with carbidopa 12.5 mg and entacapone 200 mg – **5% DV Jul-25 to 2027**	27.01	100	**Stalevo**
Tab 100 mg with carbidopa 25 mg and entacapone 200 mg – **5% DV Jul-25 to 2027**	34.18	100	**Stalevo**
Tab 150 mg with carbidopa 37.5 mg and entacapone 200 mg – **5% DV Jul-25 to 2027**	44.96	100	**Stalevo**
Tab 200 mg with carbidopa 50 mg and entacapone 200 mg – **5% DV Jul-25 to 2027**	51.23	100	**Stalevo**

125 CLOMIPRAMINE HYDROCHLORIDE (new listing and addition of PSS)

Tab 25 mg – **5% DV Jul-25 to 2027**	16.99	50	**APO Clomipramine**

125 CLOMIPRAMINE HYDROCHLORIDE (delisting)

Tab 10 mg	10.17	30	Clomipramine Teva
Tab 25 mg	11.99	30	Clomipramine Teva
Cap 10 mg	35.50	28	Clomipramine Teva
Cap 25 mg	35.50	28	Clomipramine Teva

Note – Clomipramine Teva tab 10 mg and 25 mg and cap 10 mg and 25 mg to be delisted from 1 July 2025.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

158 CARBOPLATIN (new listing)

Inj 10 mg per ml, 45 ml vial	25.73	1	DBL Carboplatin

163 PAZOPANIB (amended restriction criteria)

➔ Tab 200 mg – **5% DV May-25 to 2027**	172.88	30	**Pazopanib Teva**
	1,334.70		Votrient
➔ Tab 400 mg – **5% DV May-25 to 2027**	464.00	30	**Pazopanib Teva**
	2,669.40		Votrient

Restricted
Initiation
Re-assessment required after 3 months
Either:
1 All of the following**:**
1.1 The patient has metastatic renal cell carcinoma **of predominantly clear cell histology**; and
1.2 ~~Any of the following~~ **Either**:
1.2.1 The patient is treatment naïve; or
1.2.2 The patient has only received prior cytokine treatment; ~~or~~ **and**
~~2.3 Both:~~
~~2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and~~
~~2.3.2 The cancer did not progress whilst on sunitinib; and~~
1.3 The patient has ~~good performance status~~ ~~(WHO/~~ **an** ECOG **performance score of** ~~grade~~ 0-2~~)~~; and
~~1.4 The disease is of predominant clear cell histology; and~~
The patient has intermediate or poor prognosis defined as:

continued...

Changes to Section H Part II – effective 1 February 2025 (continued)

continued...

~~1.5~~ **1.4** Any of the following:
- 1.4.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
- 1.4.2 Haemoglobin level < lower limit of normal; or
- 1.4.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
- 1.4.4 Interval of < 1 year from original diagnosis to start of systemic therapy; or
- 1.4.5 Karnofsky performance score of less than or equal to 70; or
- 1.4.6 2 or more sites of organ metastasis; **or**

2 All of the following:
- **2.1 The patient has metastatic renal cell carcinoma; and**
- **2.2 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and**
- **2.3 The cancer did not progress whilst on sunitinib; and**
- **2.4 Pazopanib to be used for a maximum of 3 months.**

Continuation
Re-assessment required after 3 months
~~Both:~~
1 No evidence of disease progression.~~; and~~
~~2 The treatment remains appropriate and the patient is benefitting from treatment.~~
~~Note: Pazopanib should be stopped if disease progresses.~~
~~Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.~~

165 SUNITINIB (amended restriction criteria – affected criteria shown only)

➔ Cap 12.5 mg	208.38	28	Sunitinib Pfizer
➔ Cap 25 mg	416.77	28	Sunitinib Pfizer
➔ Cap 50 mg	694.62	28	Sunitinib Pfizer

Restricted
Initiation – (RCC)
Re-assessment required after 3 months
All of the following:
1 The patient has metastatic renal cell carcinoma **of predominantly clear cell histology**; and
2 Any of the following:
- 2.1 The patient is treatment naïve; or
- 2.2 The patient has only received prior cytokine treatment; or
- 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial with has Ethics Committee approval; or
- 2.4 Both:
  - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
  - 2.4.2 The cancer did not progress whilst on pazopanib; and

3 The patient has ~~good performance status (WHO/~~ **an** ECOG **performance score of** ~~grade~~ 0-2~~)~~; and
~~4 The disease is of predominant clear cell histology; and~~
~~5 All of the following:~~
- ~~5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or~~
- ~~5.2 Haemoglobin level < lower limit of normal; or~~
- ~~5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or~~
- ~~5.4 Interval of < 1 year from original diagnosis to start of systemic therapy; or~~
- ~~5.5 Karnofsky performance score of less than or equal to 70; or~~
- ~~5.6 2 or more sites of organ metastasis; and~~

~~6~~**4** Sunitinib to be used for a maximum of 2 cycles.
~~Note: RCC - Sunitinib should be stopped if disease progresses.~~
~~Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.~~

continued...

Changes to Section H Part II – effective 1 February 2025 (continued)

continued...

Continuation – (RCC)
Re-assessment required after 3 months
~~Both:~~
1 No evidence of disease progression.~~; and~~
~~2 The treatment remains appropriate and the patient is benefitting from treatment.~~

253 BARICITINIB (delisted)
➔Tab 2 mg ..... 0.00 28 Olumiant
➔Tab 4 mg ..... 0.00 28 Olumiant
Note – Olumiant tab 2 mg and 4 mg delisted 1 February 2025.

RESPIRATORY SYSTEM AND ALLERGIES

255 BEE VENOM (new listing)
➔Initiation Kit - 1 vial freeze dried venom with diluent ..... 305.00 1 VENOX

255 BEE VENOM (delisting)
➔Initiation Kit - 5 vials freeze dried venom with diluent ..... 305.00 1 VENOX
Note – VENOX Initiation Kit - 5 vials freeze dried venom with diluent to be delisted from 1 May 2025.

256 FEXOFENADINE HYDROCHLORIDE (new listing and addition of PSS)
Tab 120 mg – **5% DV Jul-25 to 2027** ..... 3.49 30 **Fexaclear**
Tab 180 mg – **5% DV Jul-25 to 2027** ..... 4.10 30 **Fexaclear**

260 SALBUTAMOL (↑ price)
Aerosol inhaler, 100 mcg per dose ..... 4.18 200 dose SalAir

SENSORY ORGANS

267 DICLOFENAC SODIUM (new listing and addition of PSS)
Eye drops 0.1%, single dose – **5% DV Jul-25 to 2027** ..... 1.85 10 dose **Diclofenac Devatis**
5.54 30 dose **Diclofenac Devatis**

267 NEPAFENAC (delisting)
Eye drops 0.3%
Note – Nepafenac eye drops 0.3% to be delisted from 1 July 2025.

SPECIAL FOODS

292 ENTERAL FEED 2 KCAL/ML (delisted)
➔Liquid 10 g protein, 17.5 g carbohydrate and 10 g fat per 100 ml, bag ..... 6.50 500 ml Fresubin 2kcal HP
Note – Fresubin 2kcal HP liquid 10 g protein, 17.5 g carbohydrate and 10 g fat per 100 ml, bag delisted 1 February 2025.

292 PEPTIDE-BASED ENTERAL FEED 1KCAL/ML (delisted)
➔Liquid 4.5 g protein, 14.3 g carbohydrate and 2.8 g fat per 100 ml, bag ..... 9.60 500 ml Survimed OPD
Note – Survimed OPD liquid 4.5 g protein, 14.3 g carbohydrate and 2.8 g fat per 100 ml, bag delisted 1 February 2025.

Changes to Section H Part II – effective 1 February 2025 (continued)

292 HIGH PROTEIN ENTERAL FEED 1.2 KCAL/ML (delisted)
➔ Liquid 10 g protein, 12.9 g carbohydrate and 3.2 g fat
and 0.64 g fibre per 100 ml, bag ..... 9.60 500 ml Fresubin Intensive
Note – Fresubin Intensive liquid 10 g protein, 12.9 g carbohydrate and 3.2 g fat and 0.64 g fibre per 100 ml, bag delisted 1 February 2025.

297 PAEDIATRIC ENTERAL FEED 1 KCAL/ML (delisted)
➔ Liquid 2.5 g protein, 12.5 g carbohydrate
and 4.4 g fat per 100 ml..... 6.50 500 ml Frebini Original
Note – Frebini Original liquid 2.5 g protein, 12.5 g carbohydrate and 4.4 g fat per 100 ml delisted 1 February 2025.

297 PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML (delisted)
➔ Liquid 3.8 g protein, 18.7 g carbohydrate
and 6.7 g fat per 100 ml..... 6.50 500 ml Frebini Energy
Note – Frebini Energy liquid 3.8 g protein, 18.7 g carbohydrate and 6.7 g fat per 100 ml delisted 1 February 2025.

297 PAEDIATRIC ENTERAL FEED WITH FIBRE 1 KCAL/ML (delisted)
➔ Liquid 2.5 g protein, 12.1 g carbohydrate, 4.5g fat
and 0.8 g fibre per 100 ml..... 7.00 500 ml Frebini Original Fibre
Note – Frebini Original Fibre liquid 2.5 g protein, 12.1 g carbohydrate, 4.5g fat and 0.8 g fibre per 100 ml delisted 1 February 2025.

297 PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5 KCAL/ML (delisted)
➔ Liquid 3.8 g protein, 18.1 g carbohydrate, 6.7 g fat
and 1.1 g fibre per 100 ml..... 7.00 500 ml Frebini Energy Fibre
Note – Frebini Energy Fibre liquid 3.8 g protein, 18.1 g carbohydrate, 6.7 g fat and 1.1 g fibre per 100 ml delisted 1 February 2025.

299 ENTERAL FEED 1.5 KCAL/ML (delisted)
➔ Liquid 7.5 g protein, 17 g carbohydrate and 5.8 g fat
per 100 ml, bag ..... 9.60 1,000 ml Fresubin HP Energy
Note – Fresubin HP Energy liquid 7.5 g protein, 17 g carbohydrate and 5.8 g fat per 100 ml, bag delisted 1 February 2025.

299 ENTERAL FEED 1 KCAL/ML (delisted)
➔ Liquid 3.8 g protein, 13.8 g carbohydrate and 3.4 g fat
per 100 ml, bag ..... 6.50 1,000 ml Fresubin Original
Note – Fresubin Original liquid 3.8 g protein, 13.8 g carbohydrate and 3.4 g fat per 100 ml, bag delisted 1 February 2025.

299 ENTERAL FEED WITH FIBRE 1 KCAL/ML (delisted)
➔ Liquid 3.8 g protein, 13.0 g carbohydrate, 3.4 g fat
and 1.5 g fibre per 100 ml, bag ..... 7.00 1,000 ml Fresubin Original Fibre
Note – Fresubin Original Fibre liquid 3.8 g protein, 13.0 g carbohydrate, 3.4 g fat and 1.5 g fibre per 100 ml, bag delisted 1 February 2025.

299 ENTERAL FEED WITH FIBRE 1.5 KCAL/ML (delisted)
➔ Liquid 7.5 g protein, 16.2 g carbohydrate, 5.8 g fat
and 1.5 g fibre per 100 ml, bag ..... 9.80 1,000 ml Fresubin HP Energy Fibre
Note – Fresubin HP Energy Fibre liquid 7.5 g protein, 16.2 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bag delisted 1 February 2025.

Index
Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government